How does circulating tumor DNA (ctDNA) testing detect minimal residual disease after surgery, and is it ready to guide d

Circulating tumor DNA (ctDNA) detection for minimal residual disease (MRD) works by identifying tiny fragments of DNA shed by cancer cells into the bloodstream after the primary tumor has been surgically removed.

How it detects MRD

1. Targeting Specific Mutations: Most MRD tests are "tumor-informed," meaning they first sequence the patient’s primary tumor tissue to identify a unique set of genetic mutations.
2. Blood Analysis: After surgery, a simple blood draw is taken. Scientists look for those specific mutations within the cell-free DNA (cfDNA) found in the plasma.
3. High Sensitivity: Because the technology uses highly sensitive techniques like next-generation sequencing (NGS) or digital PCR, it can detect even a handful of molecules of tumor DNA among a vast background of healthy DNA. If these specific mutations are found, it indicates that microscopic cancer cells likely remain in the body, even if they are invisible on standard imaging scans (like CT or PET).

Is it ready to guide chemotherapy decisions?

The clinical utility of ctDNA for guiding chemotherapy is currently a major area of research, but it is not yet the universal "gold standard" for all patients. Here is where the field stands:

• Clinical Trials: Multiple large-scale, randomized clinical trials (such as DYNAMIC in colon cancer) have shown that using ctDNA to guide treatment can reduce the number of patients receiving unnecessary chemotherapy without compromising outcomes. In some cases, patients who are ctDNA-negative can safely "de-escalate" or skip chemotherapy.
• Regulatory Context: While oncologists are increasingly using ctDNA assays in clinical practice, many health systems and regulatory bodies (like the FDA) are still defining the precise criteria for its use as a primary decision-making tool.
• Challenges: There are still nuances being worked out, such as the timing of the tests, the risk of "false negatives" (where the tumor doesn't shed enough DNA to be detected), and the potential for "false positives" (e.g., DNA from non-cancerous processes).

The Bottom Line: For many types of cancer—especially colorectal cancer—ctDNA testing is increasingly viewed as a valuable tool to help doctors and patients decide whether to pursue adjuvant chemotherapy. However, it is typically used as a supplement to existing clinical information (like tumor stage, grade, and histology) rather than a replacement for professional clinical judgment. You should discuss with your oncologist whether a ctDNA assay is appropriate for your specific cancer type and clinical situation.